11/21
05:31 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/19
08:47 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
11/12
08:00 am
rvph
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
Low
Report
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
11/10
08:18 am
rvph
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis [Yahoo! Finance]
Medium
Report
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis [Yahoo! Finance]
11/10
08:00 am
rvph
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
Medium
Report
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
10/29
08:00 am
rvph
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
Low
Report
Reviva to Participate in the Spartan Capital Securities Second Annual Investor Conference
10/28
02:23 pm
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
Low
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
10/28
08:00 am
rvph
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Medium
Report
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
10/27
08:06 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by analysts at HC Wainwright from $11.00 to $4.00. They now have a "buy" rating on the stock.
Low
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by analysts at HC Wainwright from $11.00 to $4.00. They now have a "buy" rating on the stock.
10/7
06:24 pm
rvph
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners [Yahoo! Finance]
High
Report
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners [Yahoo! Finance]
10/7
04:08 pm
rvph
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
High
Report
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
10/4
03:06 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at
Wall St
High
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at
Wall St
10/2
08:00 am
rvph
Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
High
Report
Reviva to Participate in the 4th Annual Roth Healthcare Opportunities Conference
9/29
08:05 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $2.00 price target on the stock.
Low
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $2.00 price target on the stock.
9/23
08:26 am
rvph
Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference [Yahoo! Finance]
Medium
Report
Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference [Yahoo! Finance]
9/23
08:00 am
rvph
Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
Medium
Report
Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
9/19
08:07 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by analysts at D. Boral Capital from $3.00 to $2.00. They now have a "buy" rating on the stock.
Low
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by analysts at D. Boral Capital from $3.00 to $2.00. They now have a "buy" rating on the stock.
9/18
09:26 pm
rvph
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
High
Report
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
9/18
04:27 pm
rvph
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering [Yahoo! Finance]
High
Report
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering [Yahoo! Finance]
9/18
04:05 pm
rvph
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
High
Report
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
9/15
09:07 am
rvph
Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by analysts at Benchmark Co. from $14.00 to $7.00. They now have a "speculative buy" rating on the stock.
Medium
Report
Reviva Pharmaceuticals (NASDAQ:RVPH) had its price target lowered by analysts at Benchmark Co. from $14.00 to $7.00. They now have a "speculative buy" rating on the stock.